Randomized Trial for Mixed Acute Rejection

NCT00771875 | Completed Phase 2 Results DMC

• 1 other identifier: X05273
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 2

Brief Summary

This study is being conducted to determine how safe and effective using an immune cell (b cell) depleting therapy and/or Thymoglobulin is in patients with a kidney transplant who are experiencing certain types of rejection.

Conditions

Graft Rejection

Outcome Measures

Primary Outcomes (1)

• Number of Patients in Each Group With Any of the Following: Rejection Reversal or Recurrent Rejection

  Rejection Reversal is a return of serum creatinine to within 115% of the baseline value, or histologic reversal occurring within 14 days of initiation of treatment. Recurrent Rejection is histologic evidence of rejection noted on a biopsy specimen obtained up to 3 months after documented rejection reversal.

  1 year

Secondary Outcomes (6)

• Number of Patients With Allografts With C4d Focal Positive Pretreatment Biopsy

  Day 1

• Renal Allograft Survival

  1 year after rejection treatment

• Mean Serum Creatinine

  7, 14, 28, 60, 90 days and 1 year post therapy initiation

• Incidence of Death

  90 days

• Number of Patients With Allografts With C4d Diffuse Positive Pretreatment Biopsy

  90 days

Study Arms (3)

Rabbit Antithymocyte Globulin (RATG)

ACTIVE COMPARATOR

Rabbit Antithymocyte Globulin (RATG) All patients will receive RATG (Thymoglobulin) dosed based on CD3 count. Patients will be redosed when the cluster of differentiation 3 (CD3) count is ≥ 25. Depending on rejection severity, Thymoglobulin will be given for a maximum of 7-14 days. CD3 levels will be monitored daily. 1.5mg/kg/day over 6 hrs with 1st dose (D1) and over 4 hours for each dose thereafter. (day 1 then when CD3 levels \> 25 cells/mm3); Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care. Methylprednisolone 250 mg with 1st dose of Thymoglobulin. Methylprednisolone 125 mg on treatment day 2 subsequent corticosteroids per institution standard of care; following treatment, corticosteroid therapy will resume at the pre-rejection dose.

Drug: Rabbit Antithymocyte Globulin (RATG); Drug: Rituximab; Drug: Bortezomib; Drug: Acetaminophen; Drug: Antihistamine; Drug: Methylprednisolone

RATG/Rituximab

EXPERIMENTAL

Rabbit Antithymocyte Globulin (RATG) + Rituximab Subjects will be given 1.5mg/kg/day of RATG over 6 hrs with 1st dose (D1) and over 4 hours for each dose thereafter. (day 1 then when CD3 levels \> 25 cells/mm3); Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care. Rituximab dose of 375 mg/ m2 on day 2. Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care. Methylprednisolone 250 mg with 1st dose of Thymoglobulin. Methylprednisolone 125 mg on treatment day 2 subsequent corticosteroids per institution standard of care; following treatment, corticosteroid therapy will resume at the pre-rejection dose.

Drug: Rituximab; Drug: Acetaminophen; Drug: Antihistamine; Drug: Methylprednisolone

RATG/Bortezomib

EXPERIMENTAL

Rabbit Antithymocyte Globulin (RATG) + Bortezomib -Subjects will be given 1.5mg/kg/day of RATG over 6 hrs with 1st dose (D1) and over 4 hours for each dose thereafter. (day 1 then when CD3 levels \> 25 cells/mm3). Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care. Bortezomib will be given at a dose of 1.3 mg/m2 via IV push over 3-5 seconds on days 2, 5, 9, and 12. Methylprednisolone will be administered prior to each bortezomib dose. On days 2 and 5, administer methylprednisolone 100 mg intravenous push (IVP). On days 9 and 12, administer methylprednisolone 50 mg intravenous push (IVP). If thymoglobulin is administered the same day as bortezomib, the order of administration is- methylprednisolone, then bortezomib, then thymoglobulin.

Drug: Bortezomib; Drug: Acetaminophen; Drug: Antihistamine; Drug: Methylprednisolone

Interventions

Rabbit Antithymocyte Globulin (RATG) DRUG

All patients will receive Thymoglobulin dosed based on CD3 count. Patients will be redosed when the CD3 count is ≥ 25. Depending on rejection severity, Thymoglobulin will be given for a maximum of 7-14 days. CD3 levels will be monitored daily.

Also known as: thymoglobulin

Rabbit Antithymocyte Globulin (RATG)

Rituximab DRUG

Rituximab dose of 375 mg/ m2 on day 2. Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care.

Also known as: rituxan

RATG/Rituximab; Rabbit Antithymocyte Globulin (RATG)

Bortezomib DRUG

Patient will receive 1.3 mg/m2 via IV push over 3-5 seconds on days 2, 5, 9, and 12. Consolidation course of bortezomib will be dosed at 1.3 mg/m2 IVP X 4 doses administered on days 1, 4, 7 and 10.

Also known as: Velcade

RATG/Bortezomib; Rabbit Antithymocyte Globulin (RATG)

Acetaminophen DRUG

Patients will be premedicated with acetaminophen prior to dosing per institution standard of care.

Also known as: Tylenol

RATG/Bortezomib; RATG/Rituximab; Rabbit Antithymocyte Globulin (RATG)

Antihistamine DRUG

Patients will be premedicated with an antihistamine prior to dosing per institution standard of care.

Also known as: diphenhydramine

RATG/Bortezomib; RATG/Rituximab; Rabbit Antithymocyte Globulin (RATG)

Methylprednisolone DRUG

Methylprednisolone 250 mg with 1st dose of Thymoglobulin. Methylprednisolone 125 mg on treatment day 2 subsequent corticosteroids per institution standard of care; following treatment, corticosteroid therapy will resume at the pre-rejection dose.

Also known as: Medrol

RATG/Bortezomib; RATG/Rituximab; Rabbit Antithymocyte Globulin (RATG)

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.
• Female subject is either post-menopausal or surgically sterilized or willing to use two acceptable methods of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study.
• Male subject agrees to use an acceptable method for contraception for the duration of the study.
• Subject is between 18 and 65 years of age, inclusive.
• Subject has a transplant dysfunction indicated by an increase in creatinine of 0.3 mg/dL or 15% (lipase \>3 X ULN for kidney/pancreas recipients) over baseline necessitating an allograft biopsy to assess for allograft rejection.
• Presence of light microscopic histologic changes consistent with acute cellular rejection of a Banff 97 (2005 update) grade IA or greater and at least one of the following:
• Donor-specific antibody (DSA) positive via Luminex
• Presence of C4d in the peritubular capillaries or glomeruli
• Subject must have no known contraindications to treatment with bortezomib, boron or mannitol, thymoglobulin, or rituximab.
• Recipients of kidney or simultaneous kidney pancreas organ transplant.

You may not qualify if:

• Subject has a platelet count \< 100,000/mm3 within 7 days before enrollment.
• Subject has an absolute neutrophil count of \< 1,000/mm3 within 7 days before enrollment.
• Subject has Grade 2 peripheral neuropathy within 14 days before enrollment.
• Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure (see section 8.4), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at Screening has to be documented by the investigator as not medically relevant.
• Subject has received other investigational drugs with 14 days before enrollment
• Serious medical (other than renal disease) or psychiatric illness likely to interfere with participation in this clinical study.
• Subjects that have previously received an organ transplant other than kidney or simultaneous kidney pancreas.
• Subjects who are recipients of A-B-O incompatible transplants, all cytotoxicity (CDC) crossmatch positive transplants
• Recipients of a simultaneous kidney pancreas transplant that only have pancreas rejection.
• Subjects unable to tolerate a dose of mycophenolate mofetil 1-3g/day (or equivalent mycophenolic acid dose).
• Subjects who are anti-HIV-positive, or HBsAg-positive. Anti-Hepatitis C Virus (HCV) positive patients are excluded, except patients with negative pathologic complete remission-result.
• Recipients of a kidney from a donor who tests positive for HIV, HBsAg or anti-HCV
• History of malignancy within the past 5 years that is not considered to be cured, with the exception of localized basal cell carcinoma of the skin (excised ≥ 2 years prior to randomization)
• Subjects with current or recent severe systemic infections within the 2 weeks prior to randomization.
• Receipt of a live vaccine within 4 weeks prior to study entry

Sponsors & Collaborators

• University of Cincinnati: lead

Study Sites (2)

The Christ Hospital

Cincinnati, Ohio, 45202, United States

Location

University of Cincinnati Medical Center

Cincinnati, Ohio, 45267, United States

Location

MeSH Terms

Interventions

thymoglobulin; Rituximab; Bortezomib; Acetaminophen; Histamine Antagonists; Diphenhydramine; Methylprednisolone

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, Murine-Derived; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins; Boronic Acids; Acids, Noncarboxylic; Acids; Inorganic Chemicals; Boron Compounds; Organic Chemicals; Pyrazines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Acetanilides; Anilides; Amides; Aniline Compounds; Amines; Histamine Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Pharmacologic Actions; Chemical Actions and Uses; Physiological Effects of Drugs; Ethylamines; Benzhydryl Compounds; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Prednisolone; Pregnadienetriols; Pregnadienes; Pregnanes; Steroids; Fused-Ring Compounds; Polycyclic Compounds

Results Point of Contact

• Title: E. Steve Woodle, MD
• Organization: University of Cincinnati

woodlees@ucmail.uc.edu

513-558-6001

Study Officials

• E. Steve Woodle, MD

  University of Cincinnati

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD, FACS

Study Record Dates

• First Submitted: October 14, 2008
• First Posted: October 15, 2008
• Study Start: September 1, 2008
• Primary Completion: December 1, 2012
• Study Completion: March 1, 2013
• Last Updated: January 27, 2016
• Results First Posted: January 27, 2016

Record last verified: 2015-12

Locations

US (2)